Definium Therapeutics News - June 2026
🔴 DFTX is trading 4.1% down today after closing an upsized $805M equity offering
DFTX is trading at $42.95 (4.1% down) as investors digest the impact of a large, upsized equity raise following its recent clinical rally. • The company...
Definium Therapeutics Secures $758 Million, Advancing Late-Stage Psychiatric Pipeline
Definium Therapeutics, Inc. closed its underwritten public offering of 20,588,236 common shares. The shares were priced at $34.00 per share. The offering was...
🟢 DFTX is trading 17% up today on Phase 3 trial success and $700M equity offering
DFTX is trading 17% up at $42.19 as investors react to positive Phase 3 results for its depression drug candidate and a significant capital raise. • The stock...
🟢 DFTX is trading 6.4% up today on Phase 3 Emerge data and analyst upgrades
DFTX is trading at $38.49 (+6.38%) in pre-market following a sharp rerating driven by positive Phase 3 Emerge data for DT120 ODT in major depressive...
🔴 DFTX is trading 6.9% down today on a $500M equity offering following Phase 3 data surge
DFTX is trading 6.9% down at $34.11 in pre-market action, pulling back from yesterday's significant gains following the announcement of a ~$500 million equity...
🟢 DFTX surges 49.8% today on positive Phase 3 results, then drops in after-hours on $500M equity offering
DFTX surged 49.80% to close at $36.67 today after reporting positive topline results from its Phase 3 Emerge study of DT120 ODT in Major Depressive Disorder. •...
🟢 Definium Therapeutics, Inc. is trading 52.6% up today after positive Phase 3 Emerge results for DT120 ODT
Definium Therapeutics, Inc. is trading at $37.35 (+52.57%) after announcing positive topline Phase 3 Emerge results for DT120 ODT in major depressive...
Reports Positive Phase 3 Emerge Study Data for Depression Treatment DT120 ODT
Definium Therapeutics announced positive topline results from its Phase 3 Emerge study for DT120 ODT (lysergide), a treatment for adults with major depressive...
🟢 Definium Therapeutics, Inc. trading 13.4% up as company discusses Phase 3 Emerge study results today
Definium Therapeutics, Inc. is trading 13.4% up at $27.75 in pre-market. The company is discussing topline results from its Phase 3 Emerge study in Major...